The clinical efficacy of pemirolast potassium (Alegysal®) for cedar pollinosis (1995)

Abstract

The clinical efficacy of pemirolast potassium (Alegysal®) for cedar pollinosis was evaluated in patients who received it before the start of the pollenseason (defined as 20 or more grains of cedar pollen per cm² per day), and those who received it after the season had already started. The nasal symptoms, activities of daily living scores (ADL), symptom scores (SS), and symptom medication scores (SMS) were all evaluated in 90 evaluable patients. At the beginning of the season, sneezing, runny nose, SS and SMS were all significantly less marked or reduced in the patients who received the drug within 4 weeks before the season than those who only received it after the season had already begun. However, the degree of nasal congestion was similar in the two groups at the beginning of the season, however, the symptoms were significantly less marked in those patients receiving the drug within 4 weeks before the pollen season began. The global improvement rate (either markedly improved or moderately improved) was 52% in the preseason group and 46.6% in the post-season group. Slightly adverse reactions were also reported in 2 of 129 patients evaluated for safety. Based on these findings, Alegysal® is thus considered to be effective for the treatment of cedar pollinosis, especially when administered 4 weeks before the start of the pollen season.